Company intelligence / Profile preview

comXensor

Monrovia, California, United Statestw.linkedin.com ↗

Ownership: Private
Employees: ~250
Development stage: Other

Overview

Xencor has developed a broad pipeline of engineered monoclonal antibodies and cytokine therapeutics for cancer and autoimmune diseases. Over twenty programs are in clinical testing with several more in preclinical development. Three XmAb medicines have reached the market through partners. Lead assets include bispecific antibodies targeting immune checkpoints or tumor antigens, as well as engineered cytokines for immunomodulation

Therapeutic areas: OncologyImmunologyHematology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyCytokineProtein (engineered proteins)
Industry: Biotech

Partnerships

AtrecaCaris Life SciencesMultiple major pharma partners for marketed XmAb drugs

Beyond the preview

Go deeper on comXensor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on comXensor.

Explore the full profile